Skip to content

Rilpivirine (TMC278) matches efavirenz in phase 3 studies, with fewer side-effects

Hepatitis C epidemic in HIV-positive gay men in Netherlands seems to have levelled off

Incentives and phone follow-up could improve healthy behaviour by young people: more research needed

The future of AIDS activism: looking for sustained energy and new tactics 10 years after Durban

People with HIV/hepatitis C co-infection more likely to develop osteoporosis

Immigrants are more risk of HIV in their host country than back at home

Malawi plans 'test and treat' approach for pregnant women to cut mother-to-child HIV transmission

Protease inhibitor to raltegravir switch maintains viral suppression, but NRTI resistance lowers efficacy

Microbicides – where next?